Brian Abrahams
Stock Analyst at RBC Capital
(1.49)
# 3,357
Out of 4,944 analysts
440
Total ratings
38.82%
Success rate
-10.2%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $57 → $55 | $37.36 | +47.22% | 15 | Aug 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $60 → $63 | $46.31 | +36.04% | 21 | Aug 8, 2025 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $96 → $98 | $119.96 | -18.31% | 32 | Aug 8, 2025 | |
| ETNB 89bio | Maintains: Sector Perform | $12 → $11 | $9.42 | +16.77% | 15 | Aug 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $39 → $40 | $25.32 | +57.98% | 2 | Aug 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $430 → $405 | $388.20 | +4.33% | 55 | Aug 5, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $18 → $10 | $8.06 | +24.07% | 11 | Aug 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $688 → $695 | $559.73 | +24.17% | 33 | Aug 4, 2025 | |
| BIIB Biogen | Maintains: Outperform | $208 → $219 | $134.00 | +63.43% | 39 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $146 → $144 | $130.21 | +10.59% | 21 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $68 → $72 | $83.75 | -14.03% | 22 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $19.45 | +18.28% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $8.52 | +52.58% | 19 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $75 | $61.06 | +22.84% | 1 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $55.34 | +21.07% | 2 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $6.90 | +349.28% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $20 | $10.74 | +86.22% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.45 | +230.03% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $33 | $4.30 | +667.44% | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $58 | $9.48 | +511.81% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $37.12 | +126.29% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $12.44 | +149.20% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.66 | +81.27% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $1.55 | +158.06% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $107.30 | +33.27% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $25.10 | +59.36% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.30 | +15.83% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $32.38 | -7.35% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $10.10 | +117.82% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $7.23 | +107.47% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $4.12 | +118.45% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $64.97 | -49.21% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $28.48 | - | 4 | Dec 4, 2017 |
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $55
Current: $37.36
Upside: +47.22%
PTC Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $46.31
Upside: +36.04%
Gilead Sciences
Aug 8, 2025
Maintains: Sector Perform
Price Target: $96 → $98
Current: $119.96
Upside: -18.31%
89bio
Aug 8, 2025
Maintains: Sector Perform
Price Target: $12 → $11
Current: $9.42
Upside: +16.77%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $25.32
Upside: +57.98%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $430 → $405
Current: $388.20
Upside: +4.33%
Prothena Corporation
Aug 5, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.06
Upside: +24.07%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Sector Perform
Price Target: $688 → $695
Current: $559.73
Upside: +24.17%
Biogen
Aug 1, 2025
Maintains: Outperform
Price Target: $208 → $219
Current: $134.00
Upside: +63.43%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $146 → $144
Current: $130.21
Upside: +10.59%
Jul 30, 2025
Maintains: Sector Perform
Price Target: $68 → $72
Current: $83.75
Upside: -14.03%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $19.45
Upside: +18.28%
Jun 30, 2025
Reiterates: Outperform
Price Target: $13
Current: $8.52
Upside: +52.58%
Jun 24, 2025
Maintains: Outperform
Price Target: $35 → $75
Current: $61.06
Upside: +22.84%
Jun 3, 2025
Reiterates: Outperform
Price Target: $67
Current: $55.34
Upside: +21.07%
May 15, 2025
Reiterates: Outperform
Price Target: $31
Current: $6.90
Upside: +349.28%
May 15, 2025
Maintains: Outperform
Price Target: $21 → $20
Current: $10.74
Upside: +86.22%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.45
Upside: +230.03%
May 13, 2025
Maintains: Outperform
Price Target: $34 → $33
Current: $4.30
Upside: +667.44%
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $9.48
Upside: +511.81%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $37.12
Upside: +126.29%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $12.44
Upside: +149.20%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.66
Upside: +81.27%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $1.55
Upside: +158.06%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $107.30
Upside: +33.27%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $25.10
Upside: +59.36%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.30
Upside: +15.83%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $32.38
Upside: -7.35%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $10.10
Upside: +117.82%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $7.23
Upside: +107.47%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $4.12
Upside: +118.45%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $64.97
Upside: -49.21%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $28.48
Upside: -